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Abstract
Introduction: There is a need to assess risk of second primary cancers in prostate cancer (PCa) patients, especially since PCa
treatment may be associated with increased risk of second primary tumours.
Methods: We calculated standardized incidence ratios (SIRs) for second primary tumours comparing men diagnosed with
PCa between 1980 and 2010 in the Canton of Zurich, Switzerland (n = 20,559), and the general male population in the
Canton.
Results: A total of 1,718 men developed a second primary tumour after PCa diagnosis, with lung and colon cancer being the
most common (15 and 13% respectively). The SIR for overall second primary cancer was 1.11 (95%CI: 1.06–1.17). Site-specific
SIRs varied from 1.19 (1.05–1.34) to 2.89 (2.62–4.77) for lung and thyroid cancer, respectively. When stratified by treatment,
the highest SIR was observed for thyroid cancer (3.57 (1.30–7.76)) when undergoing surgery, whereas liver cancer was
common when treated with radiotherapy (3.21 (1.54–5.90)) and kidney bladder was most prevalent for those on hormonal
treatment (3.15 (1.93–4.87)). Stratification by time since PCa diagnosis showed a lower risk of cancer for men with PCa
compared to the general population for the first four years, but then a steep increase in risk was observed.
Conclusion: In the Canton of Zurich, there was an increased risk of second primary cancers among men with PCa compared
to the general population. Increased diagnostic activity after PCa diagnosis may partly explain increased risks within the first
years of diagnosis, but time-stratified analyses indicated that increased risks remained and even increased over time.
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Introduction
The number of men living with prostate cancer (PCa) is growing
rapidly. In the US, currently more than two million men are PCa
survivors as the disease can often be treated successfully [1]. In
Switzerland the prevalence rate of PCa was estimated to be 580.5
per 100,000 in 2010, accounting for 45,421 men living with the
disease [2]. It is therefore of public health importance to assess the
risk of second primary cancers in these men, especially since it is
thought that PCa treatment may also be associated with an
increased risk of second primary tumours [3–7].
A Swedish study based on the National Prostate Cancer
Register (NPCR) concluded that about 17% of all PCa occurred in
combination with another primary cancer (before or after PCa
diagnosis) [8]. A study based on the Israel Cancer Registry,
including 29,593 men diagnosed with PCa, found an increased risk
of rectal cancer among men treated with radiation therapy
compared to those managed by surgery [9]. However, a recent
retrospective cohort study of 24,038 US men diagnosed with
localized PCa did not find an association between androgen
deprivation therapy (ADT) and risk of second primary cancers [3].
Apart from the potential risk of adverse treatment effects, it is
also of interest to assess the risk of second primary cancers in men
with PCa to identify potential underlying etiological mechanisms
[8,10]. Given the increasing evidence for an association between
Insulin-like Growth Factor (IGF)-I and risk of PCa, the Swedish
PCBaSE study evaluated the risk of other IGF-I related cancers
(colon, rectum, thyroid, and hematologic cancers) and found an
increased risk among those men treated with ADT [8].
To further disentangle the association between PCa and risk of
second primary cancers we therefore calculated the standardized
incidence ratios (SIRs) comparing men diagnosed with PCa
between 1980 and 2010 and the general male population in the
canton of Zurich, Switzerland, while also taking into account
treatment information.
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Methods
Study population
The index cohort for this study included all men diagnosed with
primary PCa between 1980 and 2010 in the canton of Zurich,
Switzerland, as registered by the Cancer Registry Zurich and Zug
(n = 20,559) [11]. None of the cancers were diagnosed at autopsy
or co-diagnosed with another type of cancer. The Cancer Registry
Zurich and Zug covers more than 1.3 million inhabitants so that it
encompasses about one third of all registered cancer cases in
Switzerland. All cases are registered based on the International
Classification of Disease for Oncology (ICD-O) together with the
basis of diagnosis (i.e. histology, autopsy, clinical investigation).
The Cancer Registry confirmed complete and systematic match-
ing of incident cases and death records as of 1997, but for the
period prior to 1997 this distinction could not be determined for
the canton of Zurich. Coverage of the Registry is almost complete,
though there is some under-registration due to insufficient legal
regulation of cancer registration on cantonal level for the years
2007–2010 [11]. The percentage death certificate only cases
(DCO%) is estimated at 2.8% for the period 1997–2010 and the
percentage of morphologically verified cases (MV%) is 93.9% for
the period 1980–2010 [12]. The Cancer Registry also includes
data on date of diagnosis, age at diagnosis, tumour grade, mode of
detection, primary treatment, civil status as well as date of death.
Diagnoses of first primary cancer after PCa were also taken from
the Cancer Registry [11]. These were categorized according to the
Eurostat European shortlist for cause of death [13].
In addition to overall cancer, we also studied those specific
cancer types. The comparison cohort or background population
consisted of all men alive in Zurich between 1980 and 2010,
divided into 5-year age-categories ending at 85+.
Statistical Methods
Since the Cancer Registry of Zurich is based on the entire
Zurich population it was possible to calculate standardized
incidence ratios (SIRs) to compare the risk of a second primary
tumour in the PCa patient group with the risk of a primary tumour
in the male population of the canton of Zurich. The SIR is defined
as the ratio of the observed numbers of primary tumours to the
expected numbers. The observed number of primary tumours was
counted among the index cohort by age (5-year categories) and
calendar-time categories (split per year). The expected number of
primary tumours was counted among the comparison cohort by
multiplying the time of follow-up with the corresponding age- and
period-specific incidence rates. The time of follow-up was taken
from the observed numbers and the age- and period-specific
incidence rates (5-year age categories and per year calendar time)
were defined as the number of cases in the comparison cohort
divided by the corresponding person-time in this cohort. The 95%
confidence intervals for the SIRs were estimated by assuming that
the observed cases had a Poisson distribution using Byar’s normal
approximation [14,15]. We performed stratified analyses by
Table 1. Baseline characteristics of men with primary PCa in the canton of Zurich, Switzerland, 1980–2010.
All men with PCa (N=20,559)
PCa men with second primary
tumour (N=1,718)
PCa men without second
primary tumour (N=18,841)
Age (years)
Mean (SD) 71.65 (9.20) 71.35 (7.68) 71.67 (9.33)
,65 5018 (24.41) 328 (19.09) 4690 (24.89)
65–74 8076 (39.28) 848 (49.36) 7228 (38.36)
75–84 5904 (28.72) 480 (27.94) 5424 (28.79)
85+ 1561 (7.59) 62 (3.61) 1499 (7.96)
Civil status
Married/Partnership 11511 (55.99) 1112 (64.73) 10399 (55.19)
Single/Widowed/Divorced/Separated 4146 (20.17) 372 (21.65) 3774 (20.03)
Others/Unknown 4902 (23.84) 234 (13.62) 4668 (24.78)
PCa Grade
I 3724 (18.11) 464 (27.01) 3260 (17.30)
II 9233 (44.91) 788 (45.87) 8445 (44.82)
III 5279 (25.68) 307 (17.87) 4987 (26.47)
IV 15 (0.00) 159 (9.25) 2149 (11.41)
Unknown/Missing 2308 (11.11)
Primary PCa Treatment
Surgery 5381 (26.17) 554 (32.25) 4827 (25.62)
Radiotherapy 1577 (7.67) 179 (10.42) 1398 (7.42)
Androgen Deprivation therapy 3194 (15.54) 288 (16.76) 2906 (15.42)
Missing or Surveillance 10407 (50.62) 697 (40.57) 9710 (51.54)
Year of diagnosis
,1995 7520 (36.58) 797 (46.39) 6723 (35.68)
1995+ 13039 (63.42) 921 (53.61) 12118 (64.32)
doi:10.1371/journal.pone.0102596.t001
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Table 2. The number of primary cancers diagnosed after primary PCa diagnosis.
ICD-10 Code Site N of primary cancers (%) (N=1,718)
C00-14 Lip, oral cavity, pharynx 42 (2.4)
C15 Oesophagus 32 (1.9)
C16 Stomach 70 (4.1)
C18 Colon 216 (12.6)
C20-21 Rectum, anus 78 (4.5)
C22 Liver, intrahepatic bile ducts 47 (2.7)
C23-24 Gallbladder, biliary tract 21 (1.2)
C25 Pancreas 79 (4.6)
C32-34 Larynx, trachea/bronchus/lung 262 (15.3)
C62 Testis 2 (0.1)
C64 Kidney, renal cell 86 (5.0)
C67 Bladder 197 (11.5)
C43 Melanoma of the skin 108 (6.3)
C44 Non-melanoma of the skin 9 (0.5)
C71-72 Brain, nervous tissue 27 (1.6)
C73 Thyroid gland 15 (0.9)
C82-85 Non-Hodgkin lymphoma 107 (6.2)
C91-95 Leukemia 76 (4.4)
C81 Hodgkin lymphoma 3 (0.2)
C90 Multiple myeloma 58 (3.4)
* Other cancers 183 (10.7)
doi:10.1371/journal.pone.0102596.t002
Table 3. Standardized Incidence Ratios (SIRs) and 95% confidence intervals (CI) for primary cancer diagnosed after primary PCa
diagnosis.
Type Observed Expected SIR 95%CI
All 1718 1545.67 1.11 1.06 1.17
lip 42 31.45 1.34 0.96 1.81
oesophagus 32 20.81 1.54 1.05 2.17
stomach 70 53.59 1.31 1.02 1.65
colon 216 124.66 1.73 1.51 1.98
anus 78 55.54 1.40 1.11 1.75
liver 47 31.65 1.49 1.09 1.97
galbladder 21 13.57 1.55 0.96 2.37
pancreas 79 46.12 1.71 1.36 2.13
lung 262 219.94 1.19 1.05 1.34
testis 2 1.87 1.07 0.12 3.85
kidney 86 35.70 2.41 1.93 2.98
bladder 197 94.26 2.09 1.81 2.40
melanoma 108 60.39 1.79 1.47 2.16
brain 27 16.22 1.66 1.10 2.42
thyroid 15 5.19 2.89 1.62 4.77
non-Hodgkin lymphomas 107 53.28 2.01 1.65 2.43
leukemia 76 41.71 1.82 1.44 2.28
Urology* 304 144.55 2.10 1.87 2.35
IGF** 416 305.55 1.36 1.23 1.50
* includes bladder, kidney, testis, and penile cancers.
** includes colon, rectum, thyroid, and haematological cancers.
doi:10.1371/journal.pone.0102596.t003
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primary treatment, grade, year of diagnosis, and time since PCa
diagnosis. For the latter analysis we performed an additional
splitting of the data by follow-up time (0.5–1 year, 2 years, 3 years,
5years, and more than 10 years).To address detection bias we also
repeated the above analyses for all urological cancers combined
(kidney, bladder, testis, and penile cancers). To evaluate potential
etiological mechanisms, we performed all analyses for all IGF-1
associated cancers (colon, rectum, thyroid, and haematological
cancers) [16]. Finally, we conducted a sensitivity analysis whereby
we excluded those tumours that occurred within 6 months of
diagnosis of the first primary tumour. The latter addresses
potential diagnostic bias and takes into account the difference
between synchronous and metachronous cancers [17]. Statistical
analyses were performed with Statistical Analysis Systems (SAS)
release 9.3 (SAS Institute, Cary, NC).
Results
The majority of men diagnosed with PCa were over 65 years
old (76%) and had a grade II tumour (45%). A more detailed
overview of patient characteristics is shown in Table 1. A total of
1,718 men developed a second primary tumour after PCa
diagnosis, with lung and colon cancer being the most common
(15 and 13%, respectively, Table 2).
Table 3 shows the SIRs for specific cancer types. Overall, there
was an increased risk of a second primary tumour among men
with PCa, compared to the general population (SIR: 1.11 (95%CI:
1.06–1.17)). Site-specific SIRs varied from 1.07 (95%CI: 1.05–
1.34) to 2.89 (95%CI: 2.62–4.77) for testicular and thyroid cancer,
respectively (Table 3).
When stratified by treatment, the highest SIR was observed for
thyroid cancer (3.57 (95%CI: 1.30–7.76)) when undergoing
surgery, whereas liver cancer was most common when treated
with radiotherapy (3.21 (95%CI: 1.54–5.90)) and kidney bladder
was most prevalent for those on hormonal treatment (3.15
(95%CI: 1.93–4.87)) (Table 4).
Stratification by tumour grade showed the highest SIR for non-
Hodgkin lymphoma (3.05 (95%CI: 2.13–4.14)) for men with a
grade I tumour, whereas for men with a grade II tumour the SIR
was highest for thyroid cancer (3.34 (95%CI: 1.44–6.58, Table 5).
Kidney cancer showed the highest statistically significant SIR for
men with a grade III/IV tumour (2.56 (95%CI: 1.52–4.05)).
For those PCa cancer diagnosed prior to 1995, the overall SIR
was 1.05 (95%CI: 0.98–1.12), whereas it was 1.17 (95%CI: 1.10–
1.25) for those diagnosed in 1995 and later on (results not shown).
Exclusion of those who have ,6 months of follow-up, resulted in
an overall SIR of 1.03 (95%CI: 0.97–1.08). The SIRs ranged from
1.14 (95%CI: 1.00–1.30) for lung cancer to 2.56 (95%CI: 1.32–
4.47) for thyroid cancer (results not shown).
Finally, we plotted SIRs by time since PCa diagnosis (Figure 1A)
which showed a lower risk of cancer for men with PCa compared
to the general population for the first four years, but then a steep
increase in risk was observed. Further stratification by primary
treatment (Figure 1B) illustrated an increase from 0.89 (95%CI:
0.51–1.45) at 2 years post diagnosis to 2.56 (95%CI: 1.84–3.46) at
more than 10 years post diagnosis for men on radiotherapy. This
increase over time was less pronounced for men undergoing
surgery or ADT: 0.86 (95%CI: 0.64–1.14) to 1.69 (95%CI: 1.37–
2.06) and 0.74 (95%CI: 0.50–1.07) to 1.32 (95%CI: 0.89–1.87),
respectively.
Discussion
The current study assessed in detail the risk of second primary
tumours for men diagnosed with PCa in the Canton of Zurich. We
found a weak increased risk for overall cancer, but a complex
pattern was observed when looking at specific cancer types and
PCa treatment and stage. Urological cancers were consistently
more prevalent among men with PCa, irrespective of their cancer
treatment or cancer stage. The increased risk of second primary
tumours increased over time and was most pronounced 10 years
post diagnosis for men who underwent radiotherapy.
Another Swiss study based on the Cancer Registries of the
Cantons of Vaud and Neuchaˆtel already investigated the risk of
second primary tumours in 1999. They compared men diagnosed
with PCa between 1974 and 1994 with the general population and
found an SIR of 0.8 (95%CI: 0.6–0.8) [18]. A more recent Swiss
study based on the Geneva Cancer Registry showed that the
overall SIR of secondary cancer in PCa patients treated with
radiotherapy was 1.35 (p= 0.056), with elevated SIRs especially
for colon cancer (4.0 (95%CI: 1.8–7.6)) [19].Our results confirm
these more recent findings; however the SIR for colon cancer was
only 1.40 and not statistically significant. The latter may be partly
due to a smaller sample size. When we computed SIRs by study
period, we observed a lower SIR of 1.05, which was not
statistically significant, for cancers diagnosed between 1980 and
1995. Thus, our inconsistency with the results by Levi et al. might
be due to the fact that in former times, PCa was often diagnosed at
an advanced stage with shorter survival. The chance of developing
a second primary tumour was lower than today. This is also
consistent with our observation of the highest SIR in men
diagnosed with stage I PCa, but a not statistically significant SIR
among men diagnosed with advanced, i.e., stage III and stage IV,
cancers.
Moreover, our results are similar compared to a Bavarian study
[10], which observed that the overall risk of second primary
tumours for men with PCa was significantly increased by 14%
compared with the general male population. With regard to
specific cancer types, a significantly increased risk was found for
cancer of the bladder, kidney, pancreas, thyroid, small intestine,
brain/nervous system, and melanoma of skin, leukemia, and
myeloma. In the Swedish study comparing all men diagnosed with
PCa between 1997–2006 and the male background population,
there was also an overall increased risk of second primary tumours
[8]. This study did not look at all cancer types as discussed in the
current project. However, they also found an increased risk for
colon, bladder, and brain cancers, as well as melanoma and non-
hodgkin lymphoma. They found a lower risk for kidney cancer,
but data reported in the Swedish study focused on the specific time
frame of five years post PCa diagnosis, whereas in our study we
have a longer follow-up. Interestingly, when investigating fatal
cancer outcomes, an American study focused on men who
underwent radical prostatectomy, found inverse association for
all deaths due to second primary malignancies [20]. These results
can however not be compared to our findings as this study by
Eifler et al. focused on fatal events in a subset of men with PCa,
who are likely to be healthier than the total PCa population and
the total male population.
Overall, there was an increased SIR for almost all cancer types.
The SIRs were especially increased for kidney, bladder, and
thyroid cancer as well as non-Hodgkin’s lymphoma. An increased
Figure 1. SIR and 95%CI (Y-axis) for all cancers occurring after PCa diagnosis by time (years) since time of PCa diagnosis (A),
stratified by treatment (B): surgery (blue), radiotherapy (red), and androgen deprivation therapy (green).
doi:10.1371/journal.pone.0102596.g001
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risk of urological cancers is consistent with previous findings and
most likely reflects the related increased diagnostic activity for PCa
men [8].
Interestingly, stratification by treatment showed some different
patterns whereby the SIRs for thyroid cancer were high for men
undergoing surgery, radiotherapy, or surveillance. Similarly, non-
Hodgkin’s lymphoma had SIRs .2 for men undergoing
surveillance and radiotherapy. In the latter group the SIR for
leukemia was also of this size. The observations for men
undergoing surveillance are difficult to interpret in this setting as
we could not distinguish between those on surveillance and those
with missing data for treatment. However, the findings for
radiotherapy are consistent with findings from the American
SEER database. Compared with men who received no PCa-
directed radiation, men who received external beam radiation
therapy were at increased risk of bladder, rectum, colon, brain,
stomach, melanoma, and lung cancer [21]. As already mentioned,
the lack of a statistically significant association for colon cancer
may be due to the lack of statistical power.
Patterns by disease stage also need to take into account patterns
by treatment as lower grade tumours are more likely to be treated
curatively with surgery or radiotherapy. Nevertheless, the SIRs for
urological cancers were consistent across grade and only slightly
higher for those undergoing radical prostatectomy; again con-
firming the increased diagnostic activity for PCa men. Further-
more, stratification by treatment as well as time since diagnosis
confirmed previous findings by Murray et al. [22]. The overall
SIR for men on radiotherapy was 1.19, but increased to 2.56 for
men followed up for more than 10 years, whereas this increase
over time was much less pronounced for men who underwent
surgery or ADT.
With respect to aetiological mechanisms, our analysis for those
cancers thought to be associated with IGF-1 showed a consistent
increased risk, also when stratified by treatment. Only for men on
ADT, there was no difference with the background population.
Men on ADT most likely had a more severe tumour and thus
lower life expectancy, which is also reflected in the analysis for
IGF-1 related cancer stratified by tumour stage. This observational
study cannot claim causality, but it supports further evidence for
the hypothesis that the IGF-1 pathway is involved in development
of epithelial cancers, as was also demonstrated in a study for
second primary tumours in patients with a head and neck cancer
[23]. Higher IGF-1 levels were associated with and increased risk
of second primary tumours with a hazard ratio of 2.78 (95%CI:
1.62–4.77).
Coverage of the Registry is almost complete, though there is
some under-registration due to insufficient legal regulation of
cancer registration on cantonal level [11]. Under-registration of
PCa cases due to limited access to two pathology institutes (4–
10%), however, only occurred between 2007 and 2010 and, thus,
only affected the most recent years of our analysis. Another
limitation is that we only have information on ‘‘radiotherapy’’ and
we cannot distinguish between external beam radiation therapy
(EBRT) and brachytherapy. Only during the last few years the
Cancer Registry started collected more detailed treatment
information (i.e. transition from curative to palliative treatment)
so that it was not possible to make further distinctions between
treatment pathways. We only collected information from time of
diagnosis. Moon et al. have previously shown that patients
receiving EBRT had a higher odds of developing cancer
compared with men receiving no radiation therapy, but the odds
was not increased for men receiving radioactive implants or
isotopes [21]. However, not all studies confirm this difference [5].
Conclusions
The current analysis showed a detailed assessment of risk of
second primary tumours following PCa diagnosis. There was a
clear increased risk, but patterns by disease stage and treatment
were complex and varied for different tumour types. Overall, the
findings illustrate the need for careful management of men with
PCa as they are more prone to develop another primary tumour.
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